Akari Therapeutics Plc
AKTX · XNASCIK 1541157fmd_13BGEACR9AMDP6EM9R7X82Z5A5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2006 to Sep 30, 2026, 50 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 1 | 0 | – | – |
| Research and development | 17 | 23 | 12 | 9 | 9 | 9 | 4 | 5 | 7 | 3 |
| Selling, general and administrative | 10 | 12 | 12 | 8 | 9 | 8 | 14 | 11 | 10 | 9 |
| Total operating expenses | 27 | 38 | 21 | 17 | 18 | 17 | 12 | 17 | 22 | 17 |
| Operating income | (27) | (38) | (21) | (17) | (18) | (17) | (12) | (17) | (22) | (17) |
| Interest expense | 0 | 0 | – | – | – | – | – | – | 0 | 0 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 9 | 2 | 0 | 0 | 1 | (0) | (1) | 7 | 2 | (1) |
| Income before taxes | (18) | (35) | (20) | (17) | (17) | (17) | (13) | (10) | (20) | (18) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | (0) | 0 | 0 | (1) |
| Net income from continuing operations | (18) | (35) | (20) | (17) | (17) | (17) | (13) | (10) | (20) | (17) |
| Net income | (18) | (35) | (20) | (17) | (17) | (17) | (13) | (10) | (20) | (17) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |